from the December 2007 issue

'Magic' thimble predicts heart disease

An Israeli-developed, thimble-like device worn over a person's index finger has been proven by clinical studies to predict who is at high risk of developing endothelial dysfunction - a key precursor of atherosclerosis, a major component in cardiovascular disease.

Called the Endo-PAT, the device is based on PAT technology that measures subtle but significant vaso-motion changes through the pneumatic probe on the finger. It is the only non-invasive device approved by the US Food and Drug Administration that reliably detects impairment of the endothelial layer (the inner lining of blood vessels).

Endo-PAT2000 is a simple and easy to use device for assessing endothelial function. The PAT signal is recorded using Itamar Medical's non-invasive, pneumatic finger probe. The data recorded is analyzed automatically using proprietary advanced Digital Signal Processing algorithms and reports are available within seconds of completing the test. Developed and manufactured by Itamar Medical in Cesearea, the screening technology adds an important dimension to cardiac medicine by allowing physicians to reliably and non-invasively measure endothelial function and identify pathological cases of dysfunction, according to foreign researchers.

Desalination company IDE set for LSE
IDE (IHTIR May 2007) will issue Global Depository Shares (GDS). The issue is due to take place in December. Goldman Sachs International and Merrill Lynch International are the global coordinators, bookrunners and underwriters, and HSBC is the co-lead manager.

IDE did not disclose the price range for the proposed offering, but sources believe that it plans to raise up to $200 million at a company value of $500 million, before money. IDE was founded in 1965. The company develops both thermal and seawater reverse osmosis desalination - the two prevailing technologies for seawater desalination, and is active in 40 countries, including China, India, Israel, Australia, Latin America, and the US. It has designed and built more than 370 facilities to date. It added that it has an 11% market share in "those countries where Israeli companies are able to conduct business and compete on even terms with other businesses. IDE said that it posted $70.7 million revenue in 2006 and a gross profit of $26.5 million on $75.6 million in January-September 2007. It added that it would use proceeds from the IPO for specific projects including investment in the Hadera desalination facility, and anticipated mergers and acquisitions.

Reprinted from the Israel High-Tech & Investment Report December 2007

Click HERE to request further information.
Click HERE to go BACK.